GW’s cannabinoid fails in focal seizures trial
A mid-stage trial assessing an experimental cannabinoid being developed by GW Pharma for adults with focal seizures has failed to hit key targets.
Read More
Tag: cannabidivarin
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
